Pasithea Therapeutics Corp. financial data

Symbol
KTTA, KTTAW on Nasdaq
Location
Miami Beach, FL
Fiscal year end
31 December
Latest financial report
10-Q - Q3 2025 - 13 Nov 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 475% % -30%
Debt-to-equity 11% % 15%
Return On Equity -98% % -20%
Return On Assets -88% % -18%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 7,443,577 shares 488%
Common Stock, Shares, Outstanding 7,443,577 shares 612%
Entity Public Float $4,100,000 USD -61%
Common Stock, Value, Issued $743 USD 614%
Weighted Average Number of Shares Outstanding, Basic 7,443,577 shares 613%
Weighted Average Number of Shares Outstanding, Diluted 7,443,577 shares 613%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense $6,746,336 USD -25%
General and Administrative Expense $1,752,262 USD 23%
Operating Income (Loss) $13,860,683 USD 14%
Nonoperating Income (Expense) $366,207 USD -3.9%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest $13,494,476 USD 14%
Net Income (Loss) Attributable to Parent $13,494,476 USD 14%
Earnings Per Share, Basic -0.41 USD/shares 86%
Earnings Per Share, Diluted -0.41 USD/shares 86%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $4,122,953 USD -56%
Other Assets, Current $19,665 USD -80%
Assets, Current $5,529,226 USD -43%
Property, Plant and Equipment, Net $113,564 USD -14%
Operating Lease, Right-of-Use Asset $32,026 USD -93%
Intangible Assets, Net (Excluding Goodwill) $6,838,527 USD -8.4%
Goodwill $1,262,911 USD 0%
Assets $13,630,664 USD -27%
Liabilities, Current $1,377,111 USD 109%
Liabilities $1,423,982 USD 73%
Accumulated Other Comprehensive Income (Loss), Net of Tax $18,301 USD
Retained Earnings (Accumulated Deficit) $59,899,593 USD -29%
Stockholders' Equity Attributable to Parent $12,206,682 USD -31%
Liabilities and Equity $13,630,664 USD -27%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $3,055,757 USD 29%
Net Cash Provided by (Used in) Financing Activities $1,474,306 USD
Common Stock, Shares Authorized 100,000,000 shares 0%
Common Stock, Shares, Issued 7,443,577 shares 612%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $1,581,451 USD 63%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $4,223,552 USD -55%
Interest Paid, Excluding Capitalized Interest, Operating Activities $7,892 USD
Deferred Tax Assets, Valuation Allowance $0 USD
Deferred Tax Assets, Gross $11,809,000 USD 55%
Operating Lease, Liability $32,989 USD -93%
Depreciation $4,000 USD -20%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent $13,442,398 USD 15%
Lessee, Operating Lease, Liability, to be Paid $33,312 USD
Property, Plant and Equipment, Gross $161,503 USD -1.9%
Operating Lease, Liability, Current $32,989 USD -80%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount $323 USD -99%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 5,000,000 shares 0%
Additional Paid in Capital $72,087,231 USD 12%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance $11,698,000 USD 54%
Share-based Payment Arrangement, Expense $97,000 USD -67%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%